In addition, although there is some literature on the relationship between specific factors such as UGT1A1 polymorphism and severe neutropenia for mFOLFIRINOX10, few studies until now have focused on the risk factors for severe neutropenia in patients treated with mFOLFIRINOX. This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.